Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.hemonc.2018.04.001
Title: Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma
Authors: de Mel, S.
Chen, Y.
Lin, A.
Soh, T.G.
Ooi, M.
Yap, E.S.
Donato, L.K.S.
Halim, N.A.A.
Mah, J.
Lim, K.
Poon, L.M.
Tan, B.
Yelly, Department of Haematology-Oncology National University Cancer Institute, National University Health System, Singapore.
Lim, H.L.
Koh, L.P.
Tai, B.C. 
Chen, Z.
Chng, W.J.
Gopalakrishnan, S.K.
Tan, L.K.
Keywords: Autologous transplantation
Chemotherapy
Stem cells
Issue Date: 2018
Publisher: King Faisal Specialist Hospital and Research Centre
Citation: de Mel, S., Chen, Y., Lin, A., Soh, T.G., Ooi, M., Yap, E.S., Donato, L.K.S., Halim, N.A.A., Mah, J., Lim, K., Poon, L.M., Tan, B., Yelly, Department of Haematology-Oncology National University Cancer Institute, National University Health System, Singapore., Lim, H.L., Koh, L.P., Tai, B.C., Chen, Z., Chng, W.J., Gopalakrishnan, S.K., Tan, L.K. (2018). Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. Hematology/ Oncology and Stem Cell Therapy 11 (4) : 225-232. ScholarBank@NUS Repository. https://doi.org/10.1016/j.hemonc.2018.04.001
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Abstract: Background: High dose Cyclophosphamide (Cy) and Vinorelbine Cyclophosphamide (Vino-Cy) are stem cell (SC) mobilisation options for patients with multiple myeloma (MM). We present a comparison of mobilisation outcomes using these regimens. Patients and methods: Vino-Cy patients received Vinorelbine 25 mg/m2 on day 1, cyclophosphamide 1500 mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10 mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000 mg/m2 on day 1 and GCSF10 mcg/kg/day from day 5 onwards. The target CD34 + SC collection was 5 × 106 per kg/BW. Results: 149 patients were included. SC collection was lower in the Vino-Cy group (8.20 × 106/Kg BW) compared to the Cy group (11.43 × 106/Kg BW), with adjusted geometric mean ratio of 0.59 (95% CI 0.41 to 0.86, p = 0.006). Time taken to achieve an adequate PB SC count was shorter for Vino-Cy (9 ± 1 day compared to 12 ± 2 days for Cy, adjusted absolute mean difference ?3.95, 95% CI ?4.85 to ?3.06, P <.001). Mobilisation related toxicities (in particular, neutropaenic fever) were greater for Cy. Conclusion: Vino-Cy is a potential alternative to Cy given the need for effective mobilisation protocols with acceptable toxicity. © 2018 King Faisal Specialist Hospital & Research Centre
Source Title: Hematology/ Oncology and Stem Cell Therapy
URI: https://scholarbank.nus.edu.sg/handle/10635/212374
ISSN: 16583876
DOI: 10.1016/j.hemonc.2018.04.001
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_hemonc_2018_04_001.pdf535.24 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

2
checked on Sep 30, 2022

Page view(s)

58
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons